Great news from our portfolio company adivo. The Munich based biotech startup announced its first development project entering first-in-patient clinical studies.
The canine monoclonal antibody is species-specific and was developed using adivo’s proprietary CAESAR technology platform. The compound targets a well-established and validated immune checkpoint inhibitor, which is of high importance for the progression of various cancer types.
As part of the clinical trial, dogs with solid tumours, including inoperable and metastatic cases, are being treated in a compassionate use setting. Primary goal is to assess safety but also early signs of efficacy.
We wish all dogs participating in the trial a speedy recovery!
More about adivo
